Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 252


Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo.

Lecka-Czernik B, Ackert-Bicknell C, Adamo ML, Marmolejos V, Churchill GA, Shockley KR, Reid IR, Grey A, Rosen CJ.

Endocrinology. 2007 Feb;148(2):903-11. Epub 2006 Nov 22.


PPARgamma2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells.

Shockley KR, Lazarenko OP, Czernik PJ, Rosen CJ, Churchill GA, Lecka-Czernik B.

J Cell Biochem. 2009 Feb 1;106(2):232-46. doi: 10.1002/jcb.21994.


Thiazolidinediones up-regulate insulin-like growth factor-1 receptor via a peroxisome proliferator-activated receptor gamma-independent pathway.

Higashi Y, Holder K, Delafontaine P.

J Biol Chem. 2010 Nov 19;285(47):36361-8. doi: 10.1074/jbc.M110.137661. Epub 2010 Sep 15.


Congenic mice with low serum IGF-I have increased body fat, reduced bone mineral density, and an altered osteoblast differentiation program.

Rosen CJ, Ackert-Bicknell CL, Adamo ML, Shultz KL, Rubin J, Donahue LR, Horton LG, Delahunty KM, Beamer WG, Sipos J, Clemmons D, Nelson T, Bouxsein ML, Horowitz M.

Bone. 2004 Nov;35(5):1046-58.


The IGF system in the neonatal ovine uterus.

Hayashi K, Carpenter KD, Welsh TH Jr, Burghardt RC, Spicer LJ, Spencer TE.

Reproduction. 2005 Mar;129(3):337-47.


Exercise Regulation of Marrow Fat in the Setting of PPARĪ³ Agonist Treatment in Female C57BL/6 Mice.

Styner M, Pagnotti GM, Galior K, Wu X, Thompson WR, Uzer G, Sen B, Xie Z, Horowitz MC, Styner MA, Rubin C, Rubin J.

Endocrinology. 2015 Aug;156(8):2753-61. doi: 10.1210/en.2015-1213. Epub 2015 Jun 8.


Changes in the insulin-like growth factor-system may contribute to in vitro age-related impaired osteoblast functions.

Kveiborg M, Flyvbjerg A, Rattan SI, Kassem M.

Exp Gerontol. 2000 Oct;35(8):1061-74.


Mutations in the NSD1 gene in patients with Sotos syndrome associate with endocrine and paracrine alterations in the IGF system.

De Boer L, Van Duyvenvoorde HA, Willemstein-Van Hove EC, Hoogerbrugge CM, Van Doorn J, Maassen JA, Karperien M, Wit JM.

Eur J Endocrinol. 2004 Sep;151(3):333-41.


The mRNA expression of the members of the IGF-system in bovine corpus luteum during induced luteolysis.

Neuvians TP, Pfaffl MW, Berisha B, Schams D.

Domest Anim Endocrinol. 2003 Nov;25(4):359-72.


DHT and testosterone, but not DHEA or E2, differentially modulate IGF-I, IGFBP-2, and IGFBP-3 in human prostatic stromal cells.

Le H, Arnold JT, McFann KK, Blackman MR.

Am J Physiol Endocrinol Metab. 2006 May;290(5):E952-60. Epub 2005 Dec 20.


Partial agonist, telmisartan, maintains PPARĪ³ serine 112 phosphorylation, and does not affect osteoblast differentiation and bone mass.

Kolli V, Stechschulte LA, Dowling AR, Rahman S, Czernik PJ, Lecka-Czernik B.

PLoS One. 2014 May 8;9(5):e96323. doi: 10.1371/journal.pone.0096323. eCollection 2014.


Rosiglitazone increases the expression of peroxisome proliferator-activated receptor-gamma target genes in adipose tissue, liver, and skeletal muscle in the sheep fetus in late gestation.

Muhlhausler BS, Morrison JL, McMillen IC.

Endocrinology. 2009 Sep;150(9):4287-94. doi: 10.1210/en.2009-0462. Epub 2009 Jun 11.


Rosiglitazone induction of Insig-1 in white adipose tissue reveals a novel interplay of peroxisome proliferator-activated receptor gamma and sterol regulatory element-binding protein in the regulation of adipogenesis.

Kast-Woelbern HR, Dana SL, Cesario RM, Sun L, de Grandpre LY, Brooks ME, Osburn DL, Reifel-Miller A, Klausing K, Leibowitz MD.

J Biol Chem. 2004 Jun 4;279(23):23908-15. Epub 2004 Apr 8.

Supplemental Content

Support Center